Source - SMW
Cell-based medicine developer MaxCyte said it expected to post a 14% increase in annual revenue to around $14m.

Ebitda for the period was expected to be in line with market expectations, while cash and cash equivalents at the year-end were $25.3m, it said, up from $11.7m in 2016.

At 9:11am: (LON:MXCT) MaxCyte Inc share price was +8p at 280p